GSK reaffirms 2026 guidance after strong first-quarter performance

GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 pharmaceuticals giant, has reiterated its full-year 2026 guidance after delivering a strong first quarter, with core operating profit growth and earnings per share both expected to rise between 7% and 9% at constant exchange rates. Turnover growth is forecast to be between 3% and 5%, supported by expectations of low double-digit growth in Specialty Medicines, offset by low single-digit declines to stable performance in both Vaccines and General Medicines.